Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma.

Esthesioneuroblastoma is rare, with limited therapeutic options when unresectable or metastatic; however, expression of somatostatin receptors qualifies it for peptide receptor radionuclide therapy (PRRT). We report outcomes of PRRT in esthesioneuroblastoma from 2 referral centers. Methods: Using PRRT databases at 2 European Neuroendocrine Tumor Society Centers of Excellence, cases were sought between 2004 and 2018 of patients who had PRRT with recurrent or metastatic esthesioneuroblastoma deemed unsuitable for further conventional therapies. Evaluations of survival and of response using a composite reference standard were performed. Results: Of 7 patients, 4 had partial response, 2 had disease stabilization, and one had early progression. Possible side effects include worsening cerebrospinal fluid leaks. Median progression-free survival was 17 mo (range, 0-30 mo), and median overall survival was 32 mo (range, 4-53 mo). Conclusion: PRRT shows promising efficacy and moderate survival duration in unresectable locally advanced or metastatic esthesioneuroblastoma warranting larger cohort studies incorporating measures of quality of life. © 2020 by the Society of Nuclear Medicine and Molecular Imaging.

Citation

Olfat Kamel Hasan, Aravind S Ravi Kumar, Grace Kong, Kira Oleinikov, Simona Ben-Haim, Simona Grozinsky-Glasberg, Rodney J Hicks. Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2020 Sep;61(9):1326-1330

Mesh Tags

Substances

PMID: 32005769

search → result